Employees: 172
Size Komipharm International (041960.KS) is a South Korea Health Care company (Biotechnology) with a market value of $454M, the 368th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩8,470 on 18 Nov 2026.
Performance Over six months the shares fell 1.9%, against -6.3% for the median peer and -37.2% for the South Korea market (cap-weighted) — 10th highest of 19 in its peer set.
Growth Revenue fell 6.5% over the last twelve months (peer median +4.9%); the operating margin is -0.8% (peer median -17.2%).
Valuation It trades at 11.8× enterprise value to sales against a peer median of 6.4× (6th most expensive of 14).
Capital Return on invested capital runs 5.8 points below its cost of capital (5.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩52.7B | ₩52.5B | ₩58.8B | ₩42.6B | ₩39.8B |
| Revenue growth | — | -11% | +38% | +7% | — |
| Gross profit | ₩17.2B | ₩15.9B | ₩20.4B | ₩11.0B | ₩9.55B |
| EBITDA | ₩2.09B | ₩2.92B | ₩8.37B | -₩2.74B | -₩438M |
| Net income | -₩6.75B | -₩7.21B | ₩13.1B | -₩3.98B | -₩6.51B |
| Free cash flow | -₩5.20B | -₩3.71B | ₩7.80B | -₩3.44B | -₩2.66B |
| Capital expenditure | ₩3.82B | ₩4.47B | ₩3.98B | ₩1.13B | ₩1.07B |
| Total debt | ₩39.3B | ₩40.7B | ₩43.8B | ₩45.1B | ₩38.1B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 041960.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.7% | -5.4% | 6th lowest of 21 |
| 6-month return | -1.9% | -6.3% | 10th highest of 19 |
| Distance from 52-week high | -28.8% | -39.7% | 6th highest of 21 |
| Revenue growth (TTM) | -6.5% | +4.9% | 5th lowest of 15 |
| Operating margin | -0.8% | -17.2% | 6th highest of 15 |
| EV / Sales | 11.8× | 6.4× | 6th most expensive of 14 |
| ROIC minus cost of capital | -5.8 pp | -8.6 pp | 5th highest of 11 |
| Net debt / EBITDA | 8.1× | -3.4× | most indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Komipharm International 041960.KS | South Korea | $454M | -2% | -6% | -1% | 11.8× | n/a | n/a |
| Shattuck Labs STTK | United States | $455M | -28% | -100% | n/a | n/a | n/a | n/a |
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | 84.4× | n/a | n/a |
| HanchorBio 7827.TW | Taiwan | $462M | n/a | n/a | -4,673% | 509.6× | n/a | n/a |
| DiaMedica Therapeutics DMAC | United States | $463M | +50% | n/a | n/a | n/a | n/a | n/a |
| EirGenix 6589.TW | Taiwan | $444M | +15% | +58% | -51% | 9.9× | n/a | n/a |
| Kamada KMDA | United States | $465M | +3% | +5% | 15% | 2.0× | 5.0% | +6.5% |
| Arvinas ARVN | United States | $443M | -26% | -12% | -10% | n/a | n/a | n/a |
| IRulya Therapeutics IRLA | United States | $440M | +88% | n/a | n/a | n/a | n/a | n/a |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $470M | n/a | n/a | n/a | n/a | n/a | n/a |
| Berry Genomics 000710.SZ | China | $439M | -17% | -2% | -24% | 3.3× | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $471M | +37% | +71% | 5% | 6.4× | 58.8% | +204.7% |
| Qingdao Vland Biotech 603739.SS | China | $437M | -24% | +5% | 7% | 2.2× | 7.7% | +7.3% |
| Scinopharm Taiwan 1789.TW | Taiwan | $435M | -2% | -5% | -4% | 4.0× | 2.1% | +0.5% |
| Neurogene NGNE | United States | $479M | -14% | -100% | n/a | n/a | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +9% | n/a | n/a | n/a | n/a | n/a |
| TaiMed Biologics 4147.TWO | Taiwan | $480M | +19% | +7% | -31% | 22.7× | n/a | n/a |
| Prothena PRTA | United States | $429M | -11% | +347% | -73% | 3.1× | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $428M | -11% | +230% | 56% | 2.6× | -19.5% | n/a |
| Crescent Biopharma CBIO | United States | $482M | -34% | n/a | -1,217% | 13.3× | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $427M | +11% | +13% | 47% | 12.3× | 5.3% | +70.5% |